Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis
Objectives Our aim was to describe the frequency and severity of infectious complications after chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL). Method…